From conventional to stealth liposomes: A new frontier in cancer chemotherapy

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 94-97

  Cattel, L ^a   Ceruti, M ^a   Dosio, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antitumor liposomes; Liposomes; Pegylated liposomal doxorubicin

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DAUNORUBICIN; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPOSOME; MACROGOL; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CONFERENCE PAPER; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOXICITY; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; IMMUNE SYSTEM;

EID: 11244317232     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.94     Document Type: Conference Paper

References (10)

1. Bangham AD. Development of the liposome concept. In: Gregoriadis G, Allison AC eds: Liposomes in biological systems, Chichester, John Wiley & Sons, chapter 1, 1980.
2. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother, 1991; 28, Suppl B: 83-91.
3. Swenson CE, Perkins WR, Roberts P, Janoff AS. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). The Breast, 2001; 10, Suppl 2: 1-7.
4. Forssen EA, Ross ME. Daunoxome® treatment of solid tumors: preclinical and clinical investigations. J Liposome Res, 1994; 4: 481-512.
5. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res, 1994; 54: 987-992.
6. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegall T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev, 1997; 24: 337-344.
7. Uster PS, Working PK, Vaage J. Pegylated liposomal doxorubicin (Doxil®, Caelyx®) distribution in tumour models observed with confocal laser scanning microscopy. Int J Pharm, 1998; 162: 77-86.
8. Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer, 2001; 91: 90-100.
9. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, Vonroenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer, 1995; 75: 2169-2173.
10. 2. Ann Oncol, 2000; 11: 1029-1033.